Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xueping Tablet plus dienogest for uterine adenomyosis
ChiCTR2200057176Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Heilongjiang University of Chinese Medicine
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Xueping tablet in adenomyosis (2 arms), sponsored by The First Affiliated Hospital of Heilongjiang University of Chinese Medicine. Primary endpoint: Visual analogue scale for dysmenorrhea. Started Feb 2022; status: recruiting.
02
Drugs
Xueping tablet
03
Conditions
adenomyosis
Beyond the preview
Go deeper on ChiCTR2200057176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057176.